SG11201504822VA - Human anti-tau antibodies - Google Patents
Human anti-tau antibodiesInfo
- Publication number
- SG11201504822VA SG11201504822VA SG11201504822VA SG11201504822VA SG11201504822VA SG 11201504822V A SG11201504822V A SG 11201504822VA SG 11201504822V A SG11201504822V A SG 11201504822VA SG 11201504822V A SG11201504822V A SG 11201504822VA SG 11201504822V A SG11201504822V A SG 11201504822VA
- Authority
- SG
- Singapore
- Prior art keywords
- human anti
- tau antibodies
- tau
- antibodies
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745410P | 2012-12-21 | 2012-12-21 | |
| PCT/US2013/076952 WO2014100600A2 (en) | 2012-12-21 | 2013-12-20 | Human anti-tau antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201504822VA true SG11201504822VA (en) | 2015-07-30 |
Family
ID=49920689
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201705104UA SG10201705104UA (en) | 2012-12-21 | 2013-12-20 | Human anti-tau antibodies |
| SG11201504822VA SG11201504822VA (en) | 2012-12-21 | 2013-12-20 | Human anti-tau antibodies |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201705104UA SG10201705104UA (en) | 2012-12-21 | 2013-12-20 | Human anti-tau antibodies |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US9598484B2 (en) |
| EP (2) | EP3792278A3 (en) |
| JP (1) | JP6284548B2 (en) |
| KR (1) | KR102234324B1 (en) |
| CN (2) | CN111205368B (en) |
| AU (1) | AU2013361107B2 (en) |
| BR (1) | BR112015014751A8 (en) |
| CA (1) | CA2896066C (en) |
| CY (1) | CY1123518T1 (en) |
| DK (1) | DK2935326T3 (en) |
| EA (1) | EA035932B1 (en) |
| ES (1) | ES2816700T3 (en) |
| HK (1) | HK1216538A1 (en) |
| HR (1) | HRP20201422T1 (en) |
| HU (1) | HUE051320T2 (en) |
| IL (1) | IL239556B (en) |
| LT (1) | LT2935326T (en) |
| MX (1) | MX2015008024A (en) |
| MY (1) | MY184251A (en) |
| PH (2) | PH12015501420B1 (en) |
| PT (1) | PT2935326T (en) |
| RS (1) | RS60899B1 (en) |
| SG (2) | SG10201705104UA (en) |
| SI (1) | SI2935326T1 (en) |
| WO (1) | WO2014100600A2 (en) |
| ZA (1) | ZA201504898B (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8940272B2 (en) | 2010-10-11 | 2015-01-27 | University Of Zurich | Human anti-tau antibodies |
| SG11201408626YA (en) | 2012-07-03 | 2015-03-30 | Univ Washington | Antibodies to tau |
| BR112015022260B1 (en) | 2013-03-13 | 2023-05-16 | Prothena Biosciences Limited | MONOCLONAL ANTIBODY THAT BINDS TO TAU, POLYNUCLEOTIDE, PHARMACEUTICAL COMPOSITION AND USE OF AN ANTIBODY |
| ZA201608812B (en) * | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| NZ727020A (en) * | 2014-06-26 | 2022-02-25 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| TW202136296A (en) | 2014-06-27 | 2021-10-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | Humanized anti-tau antibodies |
| DE102014013571A1 (en) * | 2014-09-18 | 2016-03-24 | Aj Roboscreen Gmbh | Monoclonal antibody to human TAU protein |
| CA2966964A1 (en) * | 2014-11-19 | 2016-05-26 | Michal Novak | Humanized tau antibodies in alzheimer's disease |
| WO2016137950A1 (en) * | 2015-02-24 | 2016-09-01 | Rpeptide, Llc | Anti-tau antibodies |
| JO3576B1 (en) | 2015-02-26 | 2020-07-05 | Lilly Co Eli | Antibodies to tau and uses thereof |
| RU2732122C2 (en) | 2015-06-05 | 2020-09-11 | Дженентек, Инк. | Anti-tau protein antibodies and methods of using said antibodies |
| JP6630426B2 (en) | 2015-07-06 | 2020-01-15 | ユーシービー バイオファルマ エスピーアールエル | Tau binding antibody |
| MA41669A1 (en) | 2015-07-06 | 2018-05-31 | Ucb Biopharma Sprl | Antibodies binding to tau |
| DK3430397T3 (en) | 2016-03-14 | 2022-05-02 | Biogen Int Neuroscience Gmbh | ANTIBODY-DEPENDENT CELL-MEDIATED PHAGOCYTOSE ASSAY FOR RELIABLE MEASUREMENT OF INGREGATION OF AGGREGATE PROTEINS |
| UA124148C2 (en) * | 2016-05-02 | 2021-07-28 | Протена Біосайенсіс Лімітед | Antibodies recognizing tau |
| KR102533675B1 (en) * | 2016-05-02 | 2023-05-22 | 프로테나 바이오사이언시즈 리미티드 | Tau recognition antibody |
| CN109415432B (en) | 2016-05-02 | 2022-07-08 | 普罗塞纳生物科学有限公司 | TAU immunotherapy |
| IL263433B2 (en) | 2016-06-07 | 2024-03-01 | Biogen Int Neuroscience Gmbh | Methods for treating alzheimer's disease |
| EP3487880A1 (en) | 2016-07-25 | 2019-05-29 | Biogen MA Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
| US10988529B2 (en) | 2016-08-09 | 2021-04-27 | Eli Lilly And Company | Combination therapy |
| CN110290801B (en) | 2016-12-07 | 2024-01-26 | 基因泰克公司 | anti-TAU antibodies and methods of use |
| TWI789371B (en) | 2016-12-07 | 2023-01-11 | 美商建南德克公司 | Anti-tau antibodies and methods of use |
| WO2018112362A1 (en) | 2016-12-16 | 2018-06-21 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
| KR20190134997A (en) | 2017-02-17 | 2019-12-05 | 데날리 테라퓨틱스 인크. | Anti-TAU Antibodies and Methods of Use thereof |
| JOP20180014A1 (en) | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same |
| MX2019011423A (en) | 2017-03-28 | 2019-11-01 | Genentech Inc | Methods of treating neurodegenerative diseases. |
| SG11201908085XA (en) * | 2017-03-28 | 2019-10-30 | Janssen Vaccines & Prevention Bv | Methods for detection of tau protein aggregation modulating compounds |
| SG11201910066QA (en) * | 2017-05-02 | 2019-11-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| KR102225178B1 (en) | 2017-10-16 | 2021-03-10 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Anti-tau antibodies and uses thereof |
| WO2019133799A1 (en) * | 2017-12-29 | 2019-07-04 | University Of Florida Research Foundation | Monoclonal antibodies targeting microtubule-binding domain of tau protein |
| WO2019175735A1 (en) * | 2018-03-11 | 2019-09-19 | Koorosh Shahpasand | Conformation-independent antibodies against neurotoxic tau proteins |
| EP3829634A1 (en) | 2018-07-31 | 2021-06-09 | Eli Lilly and Company | Combination therapy |
| US20210347868A1 (en) * | 2018-10-19 | 2021-11-11 | Gabriel Pascual | Anti-synuclein antibodies |
| EP3873934A2 (en) | 2018-10-29 | 2021-09-08 | Biogen MA Inc. | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport |
| KR20210090184A (en) * | 2018-11-08 | 2021-07-19 | 프로테나 바이오사이언시즈 리미티드 | Tau Recognizing Antibodies |
| WO2020252394A2 (en) * | 2019-06-13 | 2020-12-17 | Arizona Board Of Regents On Behalf Of Arizona State University | Targets and methods of diagnosing, monitoring and treating frontotemporal dementia |
| EP4004038A4 (en) * | 2019-07-23 | 2023-07-26 | Shanghaitech University | Asic1 channel antagonist antibody |
| KR102509648B1 (en) | 2019-08-06 | 2023-03-15 | 아프리노이아 테라퓨틱스 리미티드 | Antibodies that bind to pathological Tau species and uses thereof |
| JP7243851B2 (en) * | 2019-10-25 | 2023-03-22 | 東洋紡株式会社 | Laser-printable film and package using the same |
| JP2023528535A (en) | 2020-06-25 | 2023-07-04 | メルク・シャープ・アンド・ドーム・エルエルシー | High Affinity Antibodies Targeting Tau Phosphorylated at Serine 413 |
| GB202010652D0 (en) * | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | Anti-tau antibodies |
| US20240059766A1 (en) * | 2020-12-16 | 2024-02-22 | Voyager Therapeutics, Inc. | Tau binding compounds |
| WO2023028591A1 (en) | 2021-08-27 | 2023-03-02 | Genentech, Inc. | Methods of treating tau pathologies |
| WO2023099788A1 (en) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
| WO2023178049A1 (en) | 2022-03-14 | 2023-09-21 | Genentech, Inc. | Predicting neurodegenerative diseases based on speech analyses |
| WO2023250326A1 (en) | 2022-06-21 | 2023-12-28 | Genentech, Inc. | Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| JP2532858B2 (en) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | Transformed myeloma cell line |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| AU631545B2 (en) | 1988-04-15 | 1992-12-03 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| CA2078689C (en) | 1990-03-20 | 2003-02-11 | Sherie L. Morrison | Chimeric antibodies with receptor binding ligands in place of their constant region |
| DK0574395T3 (en) | 1990-11-09 | 2002-10-07 | Stephen D Gillies | Cytokine immunoconjugates |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| DK0610330T3 (en) * | 1991-10-25 | 1998-01-26 | Innogenetics Nv | Monoclonal antibodies against microtubule-associated protein tau |
| AU675661B2 (en) | 1992-07-24 | 1997-02-13 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DE69232604T2 (en) | 1992-11-04 | 2002-11-07 | City Of Hope Duarte | ANTIBODY CONSTRUCTS |
| DE69332859T2 (en) | 1992-11-13 | 2003-12-18 | Idec Pharma Corp | CONSENSUS-KOZAK SEQUENCES FOR MAMMAL EXPRESSION |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| ES2118373T3 (en) | 1992-12-14 | 1998-09-16 | Innogenetics Nv | MONOCLONAL ANTIBODIES DIRECTED AGAINST THE TAU PROTEIN ASSOCIATED WITH MICROTUBULES, HYBRIDOMES THAT SEGREGATE THESE ANTIBODIES, ANTIGEN RECOGNITION BY THESE MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS. |
| DK0737208T3 (en) | 1993-12-21 | 2006-11-27 | Innogenetics Nv | Monoclonal antibodies specific for PHF tau, hybridomas secreting them, and antigen recognition for these antibodies and their applications |
| CA2195672A1 (en) | 1994-07-29 | 1996-02-15 | Eugeen Vanmechelen | Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| WO1998022120A1 (en) | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| CZ293355B6 (en) | 1997-03-14 | 2004-04-14 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and appropriate vectors for accomplishing the same |
| JP2002512624A (en) | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | Method for producing non-immunogenic protein |
| AU1631700A (en) | 1998-11-23 | 2000-06-13 | Idec Pharmaceuticals Corporation | Tumor antigen-specific antibody-gp39 chimeric protein constructs |
| US20040110938A1 (en) * | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
| US7858559B2 (en) | 2000-11-17 | 2010-12-28 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| EP1373321A2 (en) | 2001-01-29 | 2004-01-02 | Idec Pharmaceuticals Corporation | Modified antibodies and methods of use |
| US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
| AT500379B8 (en) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | TAU PROTEINS |
| AU2002355477B2 (en) | 2001-08-03 | 2008-09-25 | Medical Research Council | Method of identifying a consensus sequence for intracellular antibodies |
| AU2002333704A1 (en) | 2001-08-24 | 2003-03-10 | Universitat Zurich | A method of inducing the formation of neurofibrillary tangles in transgenic animals |
| US20030157641A1 (en) | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
| AU2003257850A1 (en) | 2002-08-14 | 2004-03-03 | Mitsubishi Kagaku Iatron, Inc. | ANTIBODY SPECIFIC TO CENTRAL Tau-PROTEIN |
| WO2004095031A1 (en) | 2003-04-24 | 2004-11-04 | Universität Zürich | Method of monitoring immunotherapy |
| NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
| WO2005080986A1 (en) | 2004-02-18 | 2005-09-01 | University Of Iowa Research Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| JP4730584B2 (en) | 2004-12-06 | 2011-07-20 | 東亞合成株式会社 | Antibacterial peptides and their use |
| US7083854B1 (en) | 2005-05-10 | 2006-08-01 | Cornell Research Foundation, Inc. | Fibers from polymer nanoclay nanocomposites by electrospinning |
| WO2007011907A2 (en) | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
| WO2007068105A1 (en) | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
| US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| PL2436696T3 (en) | 2007-01-05 | 2017-10-31 | Univ Zuerich | Method of providing disease-specific binding molecules and targets |
| EP3348573B1 (en) * | 2008-04-25 | 2020-04-22 | Dyax Corp. | Method of producing antibodies against fcrn and use thereof |
| CN101307108B (en) * | 2008-06-25 | 2012-04-04 | 南京川博生物技术有限公司 | Anti-phosphorylation Tau protein antibody use for detecting AD sign abnormal phosphation Tau protein level |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| EP3329932A1 (en) | 2009-06-10 | 2018-06-06 | New York University | Immunological targeting of pathological tau proteins |
| WO2011053565A2 (en) | 2009-10-29 | 2011-05-05 | Biomedical Sciences Research Centre "Alexander Fleming" | Compositions and methods for detecting a tauopathy |
| DK2625198T3 (en) | 2010-10-07 | 2015-09-28 | Ac Immune Sa | Antibodies that recognize the phosphorylated tau |
| US8940272B2 (en) | 2010-10-11 | 2015-01-27 | University Of Zurich | Human anti-tau antibodies |
| CA2826286C (en) * | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| WO2012149365A2 (en) | 2011-04-27 | 2012-11-01 | Northwestern University | Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies |
| US20120323214A1 (en) * | 2012-05-16 | 2012-12-20 | Totada R Shantha | Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis |
-
2013
- 2013-12-20 EP EP20178431.1A patent/EP3792278A3/en not_active Withdrawn
- 2013-12-20 LT LTEP13818637.4T patent/LT2935326T/en unknown
- 2013-12-20 US US14/654,176 patent/US9598484B2/en active Active
- 2013-12-20 MY MYPI2015001581A patent/MY184251A/en unknown
- 2013-12-20 KR KR1020157019330A patent/KR102234324B1/en active IP Right Grant
- 2013-12-20 WO PCT/US2013/076952 patent/WO2014100600A2/en active Application Filing
- 2013-12-20 SI SI201331780T patent/SI2935326T1/en unknown
- 2013-12-20 CN CN201911004609.5A patent/CN111205368B/en active Active
- 2013-12-20 MX MX2015008024A patent/MX2015008024A/en active IP Right Grant
- 2013-12-20 BR BR112015014751A patent/BR112015014751A8/en not_active Application Discontinuation
- 2013-12-20 CA CA2896066A patent/CA2896066C/en active Active
- 2013-12-20 RS RS20201060A patent/RS60899B1/en unknown
- 2013-12-20 PT PT138186374T patent/PT2935326T/en unknown
- 2013-12-20 SG SG10201705104UA patent/SG10201705104UA/en unknown
- 2013-12-20 HU HUE13818637A patent/HUE051320T2/en unknown
- 2013-12-20 SG SG11201504822VA patent/SG11201504822VA/en unknown
- 2013-12-20 EA EA201591020A patent/EA035932B1/en unknown
- 2013-12-20 JP JP2015549784A patent/JP6284548B2/en active Active
- 2013-12-20 CN CN201380073531.7A patent/CN105324394B/en active Active
- 2013-12-20 DK DK13818637.4T patent/DK2935326T3/en active
- 2013-12-20 AU AU2013361107A patent/AU2013361107B2/en active Active
- 2013-12-20 ES ES13818637T patent/ES2816700T3/en active Active
- 2013-12-20 EP EP13818637.4A patent/EP2935326B1/en active Active
-
2015
- 2015-06-19 PH PH12015501420A patent/PH12015501420B1/en unknown
- 2015-06-21 IL IL239556A patent/IL239556B/en active IP Right Grant
- 2015-07-08 ZA ZA201504898A patent/ZA201504898B/en unknown
-
2016
- 2016-04-19 HK HK16104461.4A patent/HK1216538A1/en unknown
-
2017
- 2017-02-08 US US15/427,843 patent/US20170369560A1/en not_active Abandoned
-
2018
- 2018-06-27 US US16/020,346 patent/US20190169274A1/en not_active Abandoned
-
2019
- 2019-09-24 US US16/580,152 patent/US20200262895A1/en not_active Abandoned
-
2020
- 2020-09-07 HR HRP20201422TT patent/HRP20201422T1/en unknown
- 2020-09-09 CY CY20201100854T patent/CY1123518T1/en unknown
-
2021
- 2021-01-13 PH PH12021550083A patent/PH12021550083A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1216538A1 (en) | Human anti-tau antibodies | |
| HRP20181320T8 (en) | Human anti-tau antibodies | |
| IL264558A (en) | Anti-il-23p19 antibodies | |
| ZA201407509B (en) | Anti-fcrn antibodies | |
| HK1204571A1 (en) | Protease-regulated antibodies | |
| HK1210192A1 (en) | Anti-siglec-15 antibodies siglec-15 | |
| HK1210186A1 (en) | Anti-h7cr antibodies h7cr | |
| PL2935330T3 (en) | Anti-notch3 antibodies | |
| IL235188A0 (en) | Anti-pdgf-c antibodies | |
| GB201209584D0 (en) | Modified antibodies |